SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
XTNT reported Third Quarter 2026 results. The price and volatility reaction is pending.
XTNTearnings

Earnings reactions, page 2

Xtant Medical Holdings, Inc. (XTNT) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $24.3 million for the third quarter of 2026 (GAAP).
  • Biologics revenue was $19.3 million for the third quarter of 2026 (GAAP).
  • Gross margin for the third quarter of 2026 was 56.3% (GAAP).
  • Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share (GAAP).
  • Adjusted EBITDA was a loss of $1.5 million for the third quarter of 2026 (non-GAAP).
  • Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement grew 8% compared to the second quarter of 2026 (non-GAAP).

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →